Weekly intensive versus standard chemotherapy in untreated small cell lung cancer (SCLC) patients with good prognosis

Recruitment status	Prospectively registered
No longer recruiting	Protocol
Overall study status	Statistical analysis plan
Completed	Results
Condition category	Individual participant data
Cancer	Record updated in last year
	Overall study status Completed Condition category

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

TR6SCLC

Study information

Scientific Title

Weekly intensive versus standard chemotherapy in untreated small cell lung cancer (SCLC) patients with good prognosis

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Lung (small cell) cancer

Interventions

- 1. Intensive Regimen: Chemotherapy, cisplatin and etoposide alternating every 7 days with ifosfamide and adriamycin. A total of twelve courses, six with each drug combination.
- 2. Standard Regimen: Chemotherapy, cisplatin and etoposide alternating every 21 days with ifosfamide and adriamycin. A total of six courses, three with each drug combination.

All limited disease patients who show complete or partial response following chemotherapy receive thoracic irradiation.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Cisplatin, etoposide, ifosfamide, adriamycin

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1988

Completion date

31/12/1992

Eligibility

Key inclusion criteria

- 1. Histologically or cytologically proven SCLC
- 2. Age 75 or under
- 3. Either limited disease or extensive disease in the good prognostic category. That is have both of the following characteristics, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 and alkaline phosphatase <1.5 upper limit of normal range
- 4. Adequate renal function
- 5. No previous malignancy, except non-melanomatous skin cancer
- 6. No previous chemotherapy or radiotherapy
- 7. No medical contraindications to treatment

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1988

Date of final enrolment

31/12/1992

Locations

Countries of recruitment

England

United Kingdom

Study participating centre MRC Clinical Trials Unit London United Kingdom NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123 Lincoln's Inn Fields London United Kingdom WC2A 3PX +44 (0)207 317 5186 kate.law@cancer.org.uk

Sponsor type

Charity

Website

http://www.cancer.org.uk

ROR

https://ror.org/054225q67

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration